Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dale R Shepard

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Urology|May 11, 2010
Editorial commentDale R Shepard
Nature Reviews. Clinical Oncology|December 10, 2009
Innovations in the systemic therapy of prostate cancerDale R Shepard, Derek Raghavan
Expert Opinion on Investigational Drugs|May 26, 2010
Zibotentan for the treatment of castrate-resistant prostate cancerDale R Shepard, Robert Dreicer
Expert Review of Anticancer Therapy|June 6, 2009
Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinomaDale R Shepard, Jorge A Garcia
Comprehensive Therapy|April 19, 2003
Gender, hyperlipidemia, and coronary artery diseaseDale R Shepard, Hani Jneid, Holly L Thacker
Journal of Patient Experience|March 5, 2020
Who Needs What? Perceptions of Patients and Caregivers in Oncology Phase 1 TrialsVictoria Rezash, Janice Reed, Barbara Gedeon, et al.
Cancer Chemotherapy and Pharmacology|March 27, 2002
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient miceLalitha Iyer, Jacqueline Ramírez, Dale R Shepard, et al.
Investigational New Drugs|August 17, 2010
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinomaDale R Shepard, Matthew M Cooney, Paul Elson, et al.
British Journal of Clinical Pharmacology|January 11, 2019
Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairmentMuhammad Wasif Saif, Lee Rosen, Michelle A Rudek, et al.
Investigational New Drugs|September 22, 2017
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [<sup>14</sup>C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumorsNeeraj Gupta, Steven Zhang, Sandeepraj Pusalkar, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Urology|May 11, 2010
Editorial commentDale R Shepard
Nature Reviews. Clinical Oncology|December 10, 2009
Innovations in the systemic therapy of prostate cancerDale R Shepard, Derek Raghavan
Expert Opinion on Investigational Drugs|May 26, 2010
Zibotentan for the treatment of castrate-resistant prostate cancerDale R Shepard, Robert Dreicer
Expert Review of Anticancer Therapy|June 6, 2009
Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinomaDale R Shepard, Jorge A Garcia
Comprehensive Therapy|April 19, 2003
Gender, hyperlipidemia, and coronary artery diseaseDale R Shepard, Hani Jneid, Holly L Thacker
Journal of Patient Experience|March 5, 2020
Who Needs What? Perceptions of Patients and Caregivers in Oncology Phase 1 TrialsVictoria Rezash, Janice Reed, Barbara Gedeon, et al.
Cancer Chemotherapy and Pharmacology|March 27, 2002
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient miceLalitha Iyer, Jacqueline Ramírez, Dale R Shepard, et al.
Investigational New Drugs|August 17, 2010
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinomaDale R Shepard, Matthew M Cooney, Paul Elson, et al.
British Journal of Clinical Pharmacology|January 11, 2019
Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairmentMuhammad Wasif Saif, Lee Rosen, Michelle A Rudek, et al.
Investigational New Drugs|September 22, 2017
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [<sup>14</sup>C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumorsNeeraj Gupta, Steven Zhang, Sandeepraj Pusalkar, et al.
Pageof 3